塞来昔布对2型糖尿病大鼠非酒精性脂肪肝病相关的胰岛素抵抗的影响

发布时间：2018-04-26 20:49

本文选题：塞来昔布 + 非酒精性脂肪肝病　；参考：《中国医科大学学报》2016年01期

【摘要】：目的探讨选择性环氧合酶2(COX-2)抑制剂塞来昔布对2型糖尿病大鼠非酒精性脂肪肝病相关的胰岛素抵抗的影响。方法雄性SD大鼠36只,随机等分为对照组、模型组、模型+塞来昔布组。造模结束前1周行胰岛素耐量试验,造模结束时(共12周)取血清、肝脏组织及附睾脂肪组织。检测血清葡萄糖、胰岛素等相关生化指标;HE染色观察肝脏和脂肪组织病理改变;Western blot检测肝脏和附睾脂肪组织中COX-2蛋白的表达。结果与对照组相比,模型组血清葡萄糖、胰岛素、总胆固醇、低密度胆固醇水平、肝内甘油三酯、肝内胆固醇水平均显著高于对照组;应用塞来昔布治疗后,上述生化指标较模型组均有显著下降。模型组胰岛素抵抗指数显著高于对照组,胰岛素敏感性指数及胰岛素耐量试验显示模型组胰岛素敏感性下降,应用塞来昔布治疗后胰岛素敏感性较模型组显著改善。模型组大鼠肝指数较模型+塞来昔布组显著升高,而模型组大鼠附睾脂肪组织质量及其相对质量(EAW/BW)显著少于模型+塞来昔布组。HE染色结果显示,模型组肝细胞脂肪变性评分显著高于对照组,应用塞来昔布治疗后模型+塞来昔布组肝细胞脂肪变性程度减轻,同时附睾脂肪组织脂肪细胞面积较模型组增加。Western blot结果显示模型组中肝组织和脂肪组织COX-2相对蛋白表达量显著高于对照组和模型+塞来昔布组。结论塞来昔布具有改善2型糖尿病大鼠非酒精性脂肪肝病相关的胰岛素抵抗作用,其机制可能与抑制肝脏组织和脂肪组织的COX-2表达有关。
[Abstract]:Objective to investigate the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on insulin resistance associated with non-alcoholic fatty liver disease in type 2 diabetic rats. Methods Thirty-six male SD rats were randomly divided into control group, model group and celecoxib group. Insulin tolerance test was performed 1 week before the end of the model. Serum, liver and epididymal adipose tissue were collected at the end of the model (12 weeks). The changes of liver and adipose tissue were observed by HE staining. The expression of COX-2 protein in liver and epididymal adipose tissue was detected by Western blot. Results compared with the control group, the serum glucose, insulin, total cholesterol, low density cholesterol, intrahepatic triglyceride and intrahepatic cholesterol levels in the model group were significantly higher than those in the control group, and the serum glucose, insulin, total cholesterol and low density cholesterol levels in the model group were significantly higher than those in the control group. The above biochemical indexes were significantly decreased compared with the model group. Insulin resistance index in model group was significantly higher than that in control group, insulin sensitivity index and insulin tolerance test showed that insulin sensitivity in model group was decreased, and insulin sensitivity in model group was improved after celecoxib treatment. The liver index in the model group was significantly higher than that in the celecoxib group, while the mass of epididymal adipose tissue and its relative mass in the model group were significantly lower than those in the model celecoxib group. The results of HE staining showed that the liver index of the model group was significantly higher than that of the model celecoxib group. The fatty degeneration score of hepatocytes in the model group was significantly higher than that in the control group, and the degree of steatosis in the model celecoxib group was reduced after celecoxib treatment. At the same time, the area of adipocytes in epididymal adipose tissue increased. Western blot results showed that the relative protein expression of COX-2 in liver and adipose tissue in model group was significantly higher than that in control group and celecoxib group. Conclusion Celecoxib can improve insulin resistance related to non-alcoholic fatty liver disease in type 2 diabetic rats. The mechanism of celecoxib may be related to the inhibition of COX-2 expression in liver and adipose tissue.
【作者单位】：中国医科大学附属盛京医院第一消化内科;
【基金】：辽宁省科学技术计划项目(2010225034)
【分类号】：R575.5

【相似文献】